Stock Analysis
Swedish Exchange Growth Companies With High Insider Ownership And Earnings Growth Up To 50%
Reviewed by Simply Wall St
Amidst a backdrop of global market shifts and economic uncertainties, the Swedish stock market remains a focal point for investors seeking growth opportunities. This article will explore three Swedish exchange-listed companies that not only demonstrate robust earnings growth up to 50% but also benefit from high insider ownership, suggesting strong confidence from those closest to the company operations. In current market conditions, where insight and stability are prized, companies with substantial insider ownership may offer an added layer of reassurance for investors. High insider stakes often align leadership interests with shareholder values, potentially leading to more prudent management and promising performance trajectories.
Top 10 Growth Companies With High Insider Ownership In Sweden
Name | Insider Ownership | Earnings Growth |
CTT Systems (OM:CTT) | 16.9% | 21.6% |
BioArctic (OM:BIOA B) | 35.1% | 50.9% |
Biovica International (OM:BIOVIC B) | 12.9% | 73.8% |
Sileon (OM:SILEON) | 33.3% | 109.3% |
KebNi (OM:KEBNI B) | 37.8% | 90.4% |
edyoutec (NGM:EDYOU) | 14.6% | 63.1% |
InCoax Networks (OM:INCOAX) | 18% | 104.9% |
Calliditas Therapeutics (OM:CALTX) | 11.6% | 52.9% |
Yubico (OM:YUBICO) | 37.5% | 43.8% |
SaveLend Group (OM:YIELD) | 23.3% | 103.4% |
Underneath we present a selection of stocks filtered out by our screen.
Betsson (OM:BETS B)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Betsson AB (publ) operates an online gaming business across the Nordic countries, Latin America, Western Europe, Central and Eastern Europe, Central Asia, and internationally with a market capitalization of SEK 17.46 billion.
Operations: The company generates €974.50 million in revenue from its Casinos & Resorts segment.
Insider Ownership: 10.9%
Earnings Growth Forecast: 14.0% p.a.
Betsson AB, a Swedish company, is demonstrating robust growth with its earnings expected to increase by 14% annually. Notably, the firm's revenue is projected to outpace the Swedish market with a 9.9% yearly growth rate. Recent strategic expansions include entering Peru's regulated online casino and sports betting markets, enhancing its South American footprint alongside existing licenses in Colombia and Argentina. Insider activities show confidence with more buying than selling in recent months, although it trades at a significant discount to estimated fair value and has an unstable dividend track record.
- Get an in-depth perspective on Betsson's performance by reading our analyst estimates report here.
- Insights from our recent valuation report point to the potential undervaluation of Betsson shares in the market.
BioArctic (OM:BIOA B)
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (ticker: OM:BIOA B) is a Swedish biopharmaceutical company focused on developing biological drugs for central nervous system disorders, with a market capitalization of SEK 20.79 billion.
Operations: The company generates SEK 252.21 million from its biotechnology segment.
Insider Ownership: 35.1%
Earnings Growth Forecast: 50.9% p.a.
BioArctic, a Swedish biopharmaceutical company, is trading at 67.8% below its estimated fair value, signaling potential undervaluation. The company is anticipated to become profitable within the next three years with expected earnings growth of 50.87% annually and revenue growth forecasted at 40.8% per year—both metrics exceeding average market projections significantly. Despite recent financial setbacks in Q1 2024, with a substantial net loss compared to the previous year, insider transactions have not been significant in volume but show more buying than selling activity over the past three months. Additionally, BioArctic continues to innovate in Alzheimer's treatment as evidenced by recent approvals and strategic alliances aimed at developing new therapies.
- Click here and access our complete growth analysis report to understand the dynamics of BioArctic.
- In light of our recent valuation report, it seems possible that BioArctic is trading behind its estimated value.
AB Sagax (OM:SAGA A)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AB Sagax (publ) is a property company with operations across Sweden, Finland, France, Benelux, Spain, Germany, and other European countries, boasting a market capitalization of approximately SEK 96.21 billion.
Operations: The company generates revenue primarily through real estate rentals, amounting to SEK 4.47 billion.
Insider Ownership: 28.3%
Earnings Growth Forecast: 33.5% p.a.
AB Sagax, a Swedish real estate company, has recently completed significant fixed-income offerings totaling nearly €500 million, aimed at bolstering its green initiatives. Despite a robust 33.49% expected annual earnings growth outpacing the Swedish market's 13.8%, revenue growth projections are modest at 9.3% annually—still above the national average of 1.7%. However, financial challenges persist as debt is poorly covered by operating cash flow, and shareholder dilution occurred over the past year. The company also maintains consistent dividend payments to shareholders amidst these financial maneuvers.
- Click here to discover the nuances of AB Sagax with our detailed analytical future growth report.
- According our valuation report, there's an indication that AB Sagax's share price might be on the expensive side.
Turning Ideas Into Actions
- Gain an insight into the universe of 86 Fast Growing Swedish Companies With High Insider Ownership by clicking here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're helping make it simple.
Find out whether BioArctic is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:BIOA B
BioArctic
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
Exceptional growth potential with flawless balance sheet.